feedback

Course Director

Mike Janicek, MD
Mike Janicek, MD

Virginia G. Piper Cancer Genetic Risk Assessment Center
Arizona Oncology (US Oncology Network)
Phoenix Division
Scottsdale, Arizona

Faculty

Bradley J. Monk
Bradley J. Monk, MD, FACS, FACOG

Arizona Oncology (US Oncology Network)
University of Arizona College of Medicine
Creighton University School of Medicine at St. Joseph's Hospital
US Oncology Research Network
Phoenix, Arizona

Accredited by

Medical Learning Institute, Inc.

View Activity Materials

Activity Description

Exploiting the impact of mutations in DNA damage response (DDR) pathways on tumorigenesis has led to advances in the development of targeted therapies such as poly-ADP ribose polymerase (PARP) inhibitors for patients with relevant cancers. These agents are currently approved for several indications and are under investigation in a number of other tumor types. Increasingly, optimal care for patients with breast, ovarian, pancreatic, and other cancers must include genetic and other biomarker testing to inform risk, prognosis, and treatment selection.

This PeerView inExchange features two leading experts who share the fundamentals of DDR pathway biology and their insights into current and emerging biomarkers, genetic testing guidelines, indications, and mechanisms, as well as the latest evidence on PARP inhibitors and other novel therapeutic approaches. The experts also provide guidance on how to incorporate molecular testing into current clinical practice to ensure that patients who have or are at risk for DDR-mutant cancers receive optimal care.

Target Audience

This activity has been designed to meet the educational needs of genetic counselors, medical and clinical geneticists, laboratory researchers, nurses, physicians, physician assistants, and all medical professionals involved in the diagnosis, management, and genetic counseling of patients who have or are at risk for DDR-mutated cancers.

Educational Objectives

Upon completion of this activity, participants should be better able to:
  • Discuss key features of the DNA damage response (DDR) pathway and the rationale for therapeutic targeting of DDR mutations in patients with cancer
  • Compare current and emerging actionable mutations associated with DDR (eg, BRCA1/2) and the different testing methods used to identify these biomarkers
  • Evaluate recent clinical evidence on current and emerging agents and combinations targeting DNA repair mechanisms, including poly-ADP ribose polymerase (PARP) inhibitors
  • Describe the guidelines for genetic risk evaluation, genetic testing procedures, and pre- and post-test counseling for patients who may be at risk for a germline mutation in the DDR pathway
  • Apply guideline-based recommendations to identify patients who should receive genetic testing, provide effective genetic counseling, and tailor biomarker testing options to the individual patient’s needs

Providership, Credit, and Support


This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

This activity is supported by independent educational grants from AstraZeneca and Merck & Co., Inc.

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty Disclosures

Co-Chair & Presenter
Mike Janicek, MD
Medical Director
Virginia G. Piper Cancer Genetic Risk Assessment Center
Arizona Oncology Genetics Program
President
Arizona Oncology (US Oncology Network)
Phoenix Division
Scottsdale, Arizona

Mike Janicek, MD, has a financial interest/relationship or affiliation in the form of:
Speakers Bureau participant with AstraZeneca and Clovis Oncology.

Co-Chair & Presenter
Bradley J. Monk, MD, FACS, FACOG
Professor
Division of Gynecologic Oncology
Arizona Oncology (US Oncology Network)
University of Arizona College of Medicine
Creighton University School of Medicine at St. Joseph's Hospital
Medical Director
US Oncology Research Network - Gynecologic Program
Phoenix, Arizona

Bradley J. Monk, MD, FACS, FACOG, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Advaxis; Agenus Inc.; Amgen Inc.; Aravive; AstraZeneca; Asymmetric Therapeutics; Boston Biomedical; Chemocare; ChemoID; Circulogene; Clovis Oncology; Conjupro Bio-Pharmaceuticals; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Geistlich Pharma North America, Inc.; Genmab A/S/Seattle Genetics, Inc.; The GOG Foundation, Inc.; ImmunoGen Inc.; Immunomedics, Inc.; Incyte Corporation; Janssen Pharmaceuticals, Inc./Johnson & Johnson Services, Inc.; Laekna Health Care; Mateon Therapeutics, Inc.; Merck & Co., Inc.; Mersana Therapeutics; Myriad Genetics, Inc.; NuCana; OncoMed Pharmaceuticals, Inc.; Oncoquest Inc.; OncoSec Medical Incorporated; Perthera, Inc.; Pfizer Inc.; Precision Medicine Group; Puma Biotechnology, Inc.; Regeneron; Samumed, LLC; Takeda Pharmaceutical Company Limited; Tesaro, Inc./GlaxoSmithKline; Vascular Biogenics; and Vigeo Therapeutics, Inc.
Speakers Bureau participant with AstraZeneca; Clovis Oncology; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Janssen Pharmaceuticals, Inc./Johnson & Johnson Services, Inc.; and Tesaro, Inc./GlaxoSmithKline.

Planning Committee Disclosures

The planners from Medical Learning Institute, Inc., the accredited provider, and PeerView Institute for Medical Education, the joint provider, do not have any financial relationships with an ACCME-defined commercial interest related to the content of this accredited activity during the past 12 months unless listed below.

Content/Peer Reviewer Disclosures

The following Content/Peer Reviewer has nothing to disclose:

Theodore G. Drivas, MD, PhD

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this accredited activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2020, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.